Scientific article
OA Policy
English

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy

Published inCore evidence, vol. 11, p. 37-47
Publication date2016
Abstract

Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase.

Citation (ISO format)
DE ROUX SERRATRICE, Christine et al. Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. In: Core evidence, 2016, vol. 11, p. 37–47. doi: 10.2147/CE.S93717
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1555-1741
475views
477downloads

Technical informations

Creation09/11/2016 12:29:00
First validation09/11/2016 12:29:00
Update15/03/2023 01:04:25
Status update15/03/2023 01:04:24
Last indexation31/10/2024 05:22:45
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack